Category: Articles

Meda Pharmaceuticals Inc. is the U.S. subsidiary of Meda AB.

The Meda Pharmaceutical product portfolio is focused primarily on respiratory, allergy, central nervous system, gastroenterology, musculoskeletal, rheumatology, erectile dysfunction, and women’s health products.

Latest News

• April 2011:
  Dymista Filed with FDA
• March 2011:
  Positive Study Results Presented
• September 2009:
  MEDA introduces EDLUAR™, the first and only sublingual tablet that contains the most prescribed sleep medication, zolpidem tartrate

Career Opportunities

• Meda Pharmaceutical’s Philosophy
• Click here to view our Career Opportunities

Drug addiction is a chronic, relapsing disease that affects the brain’s reward system, leading to compulsive substance use. It can disrupt physical health, relationships, and daily functioning. Professional treatment is crucial for effective recovery, providing support, therapy, and resources to manage addiction and promote long-term well-being. If you’re looking for a methadone dr near me, it’s important to seek out qualified healthcare professionals who specialize in addiction treatment and can guide you through your recovery journey.

Understanding Drug Addiction

Definition and Types of Addiction

Drug addiction is a complex, chronic condition characterized by the compulsive use of substances despite harmful consequences. It affects brain chemistry, leading to physical and psychological dependence. There are several types of drug addiction:

• Prescription Drugs: Medications prescribed for pain, anxiety, or sleep disorders can be misused and lead to dependency. Common examples include opioids (e.g., oxycodone), benzodiazepines (e.g., alprazolam), and stimulants (e.g., Adderall).
• Illicit Substances: These include drugs like cocaine, heroin, methamphetamine, and ecstasy, which are illegal and highly addictive.
• Over-the-Counter Drugs: Medications like cough syrups or cold medicines, when abused, can cause addiction.

Causes and Risk Factors

The development of drug addiction is influenced by multiple factors:

• Biological Factors: Genetic predisposition and brain chemistry imbalances can make individuals more vulnerable to addiction.
• Environmental Factors: Exposure to substance abuse in the family or community, peer pressure, and stress can increase the risk of addiction.
• Psychological Factors: Mental health conditions such as depression, anxiety, or trauma can contribute to the development of addiction.

Signs and Symptoms

Physical Symptoms	Behavioral Symptoms	Psychological Symptoms
Slurred speech	Secretive behavior	Mood swings
Unexplained weight loss	Neglect of responsibilities	Anxiety or paranoia
Deteriorating hygiene	Withdrawal from social activities	Irritability or depression

Assessment and Diagnosis

Medical Evaluation

A thorough medical evaluation is crucial for diagnosing drug addiction. This includes a detailed history of substance use, physical examinations, and lab tests to detect substances in the body.

Diagnostic Criteria

The following criteria are used to diagnose drug addiction:

• Persistent desire or unsuccessful attempts to control substance use.
• Spending significant time obtaining, using, or recovering from the drug.
• Continued use despite negative impacts on health and relationships.

Identifying Addiction Severity

The severity of addiction is determined based on the number of criteria met, ranging from mild to severe. The evaluation helps in developing a tailored treatment plan for recovery.

Treatment Approaches

Detoxification (Detox)

Purpose: Eliminating Substances from the Body

Detoxification, or detox, is the initial step in the treatment of drug addiction, aimed at removing harmful substances from the body. This process is essential for managing withdrawal symptoms and preparing the individual for further treatment. Detox helps in clearing the drug from the system, providing a foundation for ongoing recovery.

Process

During detox, the body goes through withdrawal, where it adjusts to the absence of the substance. Medical professionals often administer medications to ease withdrawal symptoms and prevent complications. The process involves:

• Evaluation of physical health and addiction history.
• Monitoring vital signs (heart rate, blood pressure, temperature).
• Medications to manage withdrawal symptoms (e.g., for opioid or alcohol withdrawal).

Duration

The length of detox varies depending on the substance used and the individual’s physical condition. Generally, detox lasts from a few days to a week, but some individuals may require longer care, particularly if the addiction is severe or involves multiple substances.

Medical Supervision During Withdrawal

Medical supervision is crucial during detox to ensure safety and comfort. In certain cases, withdrawal symptoms can be life-threatening, especially with alcohol, opioids, and benzodiazepines, so professional oversight is necessary to manage risks effectively.

Behavioral Therapies

Behavioral therapies are a cornerstone of addiction treatment, helping individuals modify their substance-use behaviors and develop coping strategies.

Therapy	Focus	Goals
Cognitive Behavioral Therapy (CBT)	Identifying and changing negative thought patterns	To help individuals cope with triggers and cravings
Dialectical Behavioral Therapy (DBT)	Emotional regulation and interpersonal effectiveness	To manage emotions and reduce self-destructive behaviors
Motivational Interviewing	Enhancing motivation to change behavior	To strengthen personal commitment to recovery

Cognitive Behavioral Therapy (CBT)

CBT is a widely-used treatment that focuses on identifying negative thought patterns that contribute to addiction. The goal is to change these thoughts and behaviors, helping individuals cope with triggers and manage cravings. CBT is typically short-term and highly structured.

Dialectical Behavioral Therapy (DBT)

DBT is designed to help individuals regulate intense emotions, improve interpersonal skills, and manage self-destructive behaviors. This approach combines cognitive-behavioral strategies with mindfulness, making it particularly useful for those with co-occurring mental health disorders, such as borderline personality disorder.

Motivational Interviewing

Motivational interviewing is a counseling technique that helps individuals explore and resolve ambivalence about their addiction. This therapy aims to increase motivation for change by enhancing an individual’s desire to make positive decisions about their recovery.

Group and Family Therapy

Group and family therapy provide emotional support through shared experiences and offer opportunities for individuals to develop healthier relationships. Family therapy helps improve communication and resolve conflicts, while group therapy fosters a sense of community and shared accountability.

Medication-Assisted Treatment (MAT)

Overview of Medications

Medication-Assisted Treatment (MAT) involves using medications to help individuals manage addiction and reduce cravings. Common medications used in MAT include:

• Methadone: An opioid agonist used to treat opioid addiction by reducing withdrawal symptoms and cravings.
• Buprenorphine: A partial opioid agonist that reduces cravings and withdrawal symptoms.
• Naltrexone: An opioid antagonist that blocks the effects of opioids and reduces cravings.

When and How Medications Are Used

MAT is often used when detox alone is insufficient. Medications are combined with behavioral therapies to offer a comprehensive treatment approach. They are prescribed based on the substance of addiction, the severity of the condition, and the individual’s medical history.

Benefits and Risks

Benefit	Risk
Reduces cravings and withdrawal symptoms	Risk of overdose if not managed correctly
Improves retention in treatment programs	Potential for medication misuse
Increases the likelihood of long-term recovery	Side effects such as nausea, dizziness

Duration of Treatment

MAT can last for months or even years, depending on the individual’s needs and progress. For some, MAT may be a long-term solution, while others may taper off medications as they achieve stability in their recovery. Regular monitoring and adjustments are important for success.

Types of Treatment Programs

Inpatient Rehabilitation

Inpatient rehabilitation programs provide 24/7 supervision in a highly structured environment. These programs are designed for individuals who require intensive care and support throughout their recovery journey. They typically offer a range of services and have a duration of 30 to 90 days.

• 24/7 Supervision: Continuous monitoring to ensure safety and compliance.
• Structured Environment: Daily routines and strict schedules to promote recovery.
• Medical Services: On-site medical professionals available for health assessments and care.
• Intensive Therapy: Includes individual counseling, group therapy, and family therapy to address emotional and psychological aspects of addiction.
• Detox Support: Managed detoxification to help individuals safely withdraw from substances.
• Accommodation Provided: Clients stay at the treatment facility, which provides lodging and meals.
• Highest Care Level: Offers the most comprehensive and intensive care.
• Full Medical Staff: Doctors, nurses, and addiction specialists are available to assist with physical and mental health.
• Emergency Support: Immediate access to emergency care if needed.
• Medication Management: Prescription medications are managed to ensure proper use and prevent misuse.

Outpatient Programs

Outpatient programs offer more flexibility than inpatient care, allowing individuals to live at home while receiving treatment. These programs are ideal for individuals with a stable home environment who need support but do not require constant supervision.

• Flexible Scheduling: Participants can schedule treatment around their work or personal life.
• Minimal Supervision: Regular check-ins with healthcare providers, but minimal supervision compared to inpatient care.
• Maintenance Therapy: Ongoing therapy to maintain sobriety after initial treatment.
• Support Groups: Participation in group therapy or peer support groups to reinforce recovery.
• Regular Check-ins: Scheduled appointments to monitor progress and provide accountability.
• Drug Screening: Random or scheduled drug tests to ensure compliance.
• Counseling Sessions: Individual and group therapy sessions to address addiction triggers and coping mechanisms.

Intensive Outpatient Programs (IOPs)

Intensive Outpatient Programs (IOPs) provide a more structured level of care than standard outpatient treatment but allow individuals to live at home. IOPs are ideal for those who require more intensive support but still need to maintain their daily responsibilities.

• Multiple Weekly Sessions: Typically involves 3-5 treatment sessions each week.
• Live at Home: Participants can continue living at home while attending treatment.
• Work Compatible: The program is designed to accommodate work schedules.
• Drug Testing: Regular drug screenings to monitor substance use.
• Group Therapy: Focus on peer support and shared recovery experiences.
• Individual Counseling: One-on-one sessions with a therapist to address personal issues.
• Flexible Schedule: The program allows flexibility to balance work, family, and therapy.
• Support Groups: Additional group sessions to offer community and shared support.

Partial Hospitalization Programs (PHP)

Partial Hospitalization Programs (PHP) offer daily treatment while allowing participants to return home in the evenings. PHPs are suitable for individuals who need intensive care but have a stable home environment.

• Daily Treatment: Intensive therapy sessions conducted throughout the day.
• Return Home Nights: Participants return home each evening after treatment.
• Medical Supervision: Continuous medical oversight to ensure safety during treatment.
• Structured Program: A highly organized program with set treatment schedules.
• Therapy Sessions: Daily individual or group therapy to address addiction and underlying issues.
• Medication Management: Ensuring that medications are taken as prescribed.
• Skills Training: Development of coping and life skills to support long-term recovery.
• Crisis Intervention: Immediate intervention if a crisis arises during treatment.

Residential Treatment

Residential treatment programs provide comprehensive care in a live-in setting. These programs can be either long-term or short-term, offering different levels of care based on the individual’s needs.

Long-term Residential Treatment

Long-term residential programs typically involve stays of 6 to 12 months, focusing on building life skills and reintegration into society.

• 6-12 Months Stay: Extended stay in a therapeutic community environment.
• Community Living: Support from peers and staff to foster accountability and growth.
• Skill Development: Focus on learning essential life skills to maintain sobriety.
• Reintegration Focus: Preparing individuals to return to society with the tools needed for long-term recovery.
• Comprehensive Care: Medical, therapeutic, and vocational support provided throughout the program.
• Behavioral Therapy: Intensive therapy sessions aimed at addressing the root causes of addiction.
• Vocational Training: Programs to help individuals gain skills for employment and independent living.
• Social Support: Emphasis on building a supportive network within the recovery community.

Short-term Residential Treatment

Short-term residential programs offer intensive treatment for 3 to 6 weeks, focusing on stabilization and transition planning.

• 3-6 Weeks Stay: A focused period for intensive treatment and therapy.
• Intensive Treatment: High level of care to address immediate addiction needs.
• Transition Planning: Preparation for ongoing treatment after residential care.
• Aftercare Focus: Planning for continuing recovery once the residential treatment is completed.
• Medical Supervision: Regular oversight to ensure physical health and safety during treatment.
• Therapy Sessions: Individual and group therapy to address addiction and mental health issues.
• Family Involvement: Family therapy to rebuild relationships and foster support in recovery.

Cost and Insurance

Treatment Costs

The cost of addiction treatment can vary widely based on the type of program, duration of stay, and level of care needed. The following table outlines general cost estimates for different types of treatment programs:

Program Type	Cost Estimate (Per Day)	Duration
Inpatient Rehabilitation	$500 – $1,000	30-90 days
Outpatient Programs	$100 – $500	Ongoing treatment
Intensive Outpatient Programs (IOP)	$250 – $600	3-5 days per week
Partial Hospitalization Programs (PHP)	$200 – $500	Daily, return home nights
Residential Treatment	$150 – $700	3-12 months

Insurance Coverage

Many health insurance plans cover addiction treatment, including inpatient and outpatient programs, as well as medications used in treatment. Insurance plans may cover treatment costs in full or partially, depending on the type of coverage and the provider. It is important to confirm the specific coverage details with the insurance provider before beginning treatment.

Financial Assistance Option

For those without insurance or sufficient coverage, several financial assistance programs can help offset the cost of treatment. These may include:

• Sliding scale fees based on income
• Government-funded programs such as Medicaid
• Non-profit organizations offering grants or scholarships

Recovery and Aftercare

Support Groups

Support groups like Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) are essential in providing ongoing support after treatment. These programs offer a community of individuals who share similar experiences and challenges, fostering encouragement and accountability in maintaining sobriety.

Role of Family, Friends, and Peer Support Groups

Family, friends, and peer support groups play a critical role in long-term recovery by providing emotional support, encouragement, and a sense of accountability. Family therapy and communication can help rebuild trust and foster a supportive environment for the recovering individual.

Community Resources and Helplines

Numerous community resources and helplines are available to support individuals in recovery. These resources include local recovery centers, mental health services, and national helplines that provide immediate assistance, counseling, and referrals to treatment programs.

Relapse Prevention Strategies

• Developing healthy coping mechanisms
• Identifying and avoiding triggers
• Creating a structured daily routine
• Staying involved in support groups
• Maintaining open communication with a counselor or sponsor

Long-term Recovery Plans

A long-term recovery plan includes ongoing therapy, continued participation in support groups, and regular check-ins with healthcare providers to ensure continued sobriety and mental health stability. It is essential for individuals to stay engaged in their recovery journey, maintaining focus on their goals and well-being.

Holistic and Alternative Treatment Approaches

Yoga, Meditation, and Mindfulness Practices

Holistic treatment approaches, such as yoga, meditation, and mindfulness practices, are increasingly being incorporated into addiction recovery programs. These practices aim to heal the mind and body, reducing stress, anxiety, and cravings while promoting emotional well-being.

• Yoga: Helps individuals develop physical and mental strength, improve flexibility, and manage stress.
• Meditation: Aids in mindfulness, helping individuals stay present, reduce negative thoughts, and improve emotional regulation.
• Mindfulness Practices: Teach individuals to focus on the present moment, which can reduce impulsivity and cravings, supporting long-term recovery.

Nutrition and Physical Wellness Programs

A healthy body is essential to successful addiction recovery, and nutrition and physical wellness programs play a vital role in the rehabilitation process. Proper nutrition helps repair the body after the damaging effects of substance abuse, while physical activity promotes overall health.

• Nutrition Counseling: Offers personalized plans to help individuals restore their physical health and energy levels after detox.
• Physical Exercise: Regular physical activity such as walking, swimming, or strength training supports mental health, reduces stress, and improves mood.
• Holistic Health Education: Teaches individuals how to take care of their bodies and minds to sustain recovery.

Art and Music Therapy

Art and music therapy are creative and therapeutic approaches that provide emotional release and self-expression. These therapies can help individuals process difficult emotions, reduce stress, and promote healing.

• Art Therapy: Encourages individuals to express themselves visually, which can help process trauma and emotions linked to addiction.
• Music Therapy: Uses music to improve mood, reduce anxiety, and provide a non-verbal way of expressing emotions.

Conclusion

Recovery from drug addiction requires a comprehensive approach that addresses the physical, emotional, and psychological aspects of the individual. Traditional treatments like therapy and medication are essential, but holistic and alternative therapies such as yoga, nutrition counseling, and creative therapies offer added benefits to enhance overall well-being. It’s crucial to remain committed to the recovery process and reach out for support when needed. Seeking professional help and embracing a well-rounded treatment plan can significantly improve the chances of long-term success and sobriety.

Key Features

Toxin Rid is a detox product designed to help people clear toxins from their bodies, especially THC from marijuana. It offers a range of programs, from one to ten days, depending on how much toxin exposure someone has had. This makes it useful for people who need to pass different types of drug tests, such as urine, saliva, or hair tests. One of the best features of Toxin Rid is that it uses natural ingredients like kelp, alfalfa leaf extract, and psyllium husk powder, which work with the body’s natural detoxification process. This makes it a safer alternative to synthetic products or extreme detox methods.

For people who want to pass a drug test without raising suspicion, Toxin Rid can be a great solution. It’s easy to use and includes three steps: pre-rid tablets, a liquid detox, and dietary fiber. The pills are taken regularly, along with a healthy diet and lots of water. By sticking to the program, users can flush out toxins from their system.

The detox programs vary based on the user’s needs, with longer courses recommended for heavy cannabis users. Overall, Toxin Rid is known for its effectiveness, and many customers have successfully passed drug tests after using it. However, it’s important to follow the instructions carefully to get the best results. For more details, you can refer to the Allergy Society of South Africa review on Toxin Rid.

Purpose

What is Toxin Rid?

Toxin Rid is a detox product designed to help people eliminate toxins from their bodies, especially THC, the active substance in marijuana. It’s especially useful for people who need to pass drug tests, whether for a job or other important reasons. With more employers requiring drug screenings, even in places where marijuana is legal, failing a test can cost someone a great job opportunity.

How Does Toxin Rid Work?

Toxin Rid works by using a natural detox process to remove THC and other toxins. It’s different from other methods, like synthetic urine, which can be risky or illegal to use. Toxin Rid has a three-part system that includes pills, a detox liquid, and fiber supplements. These work together to clean the body from the inside out.

Who Should Use Toxin Rid?

People who have smoked marijuana and are facing a drug test in the near future can benefit from Toxin Rid. The product has detox programs that last anywhere from 1 to 10 days. The longer the program, the more effective it is for heavy users. Lighter smokers may find success with shorter programs, like the 1 or 2-day detox.

Why Choose Toxin Rid?

Unlike other detox products, Toxin Rid uses natural ingredients like kelp, alfalfa, and fiber to help your body get rid of toxins. Many users report passing urine, saliva, and even hair drug tests after using it. With positive reviews and safe, natural ingredients, Toxin Rid is a popular choice for people looking to detox and pass drug tests without damaging their bodies.

Usage Instructions

Toxin Rid is a detox program designed to help individuals remove toxins from their bodies, particularly THC, which is the active ingredient in marijuana. It’s commonly used by people who need to pass drug tests for jobs. The detox process typically spans from 1 to 10 days, depending on how much marijuana you’ve consumed and how quickly you need to be toxin-free.

Using Toxin Rid is straightforward. For 10 days, users take 15 pills daily—three pills every five hours. Along with the pills, users can drink detox fluid and take dietary fiber supplements for better results. On the day of the test, users mix water with the provided detox drink and dietary fiber supplement, drink it, and follow it up with more water to flush out the toxins.

The goal is to eliminate THC from the body naturally without the use of synthetic urine or other risky methods. Reviews suggest that Toxin Rid can be highly effective for passing urine, saliva, or blood tests. However, it’s important to follow the instructions carefully and maintain a healthy diet and hydration throughout the detox process for the best results.

While the product has received many positive testimonials, it’s not guaranteed to work for everyone. The success of the detox program can depend on several factors, including individual body chemistry and toxin levels. Despite this, Toxin Rid is considered a safe and reliable method to detox for drug tests.

Ingredients

If you’re looking for a natural way to cleanse your body of toxins, especially from marijuana, Toxin Rid might be a good choice. This detox product includes a blend of natural ingredients designed to support the body’s natural detoxification process. Here’s a closer look at what’s inside Toxin Rid and how these ingredients help.

Kelp is one of the key components in Toxin Rid. Kelp is a type of seaweed rich in iodine, which supports your thyroid gland. The thyroid is important for regulating your metabolism, and a healthy metabolism helps your body get rid of toxins more efficiently.

Alfalfa leaf extract is another ingredient in Toxin Rid. Alfalfa is known for its detoxifying properties. It helps purify your blood and supports liver health. Your liver plays a crucial role in breaking down toxins, so keeping it healthy is essential for a successful detox.

Psyllium husk powder is included as well. This is a type of dietary fiber that helps promote healthy digestion. It works by moving toxins through your digestive system, helping to flush them out of your body.

In addition to these natural ingredients, Toxin Rid also contains important minerals like iron, calcium, magnesium, sodium, and potassium. These minerals help replenish your body’s electrolytes, which can be lost during the detox process. They also support overall bodily functions and help keep you hydrated, which is important when you’re trying to remove toxins.

Overall, Toxin Rid’s combination of natural ingredients and essential minerals makes it a popular choice for people looking to detoxify their bodies and pass drug tests.

Pros and Cons

Pros

Toxin Rid is a popular choice for those needing to pass drug tests, and it has several advantages:

1. Effective Detoxification: Many users have reported success with Toxin Rid, noting its effectiveness in clearing THC and other toxins from the body. This includes passing various types of drug tests, such as those for marijuana, alcohol, and even blood tests.
2. Natural Ingredients: The product is made from natural components like kelp, alfalfa leaf extract, and psyllium husk powder. These ingredients support detoxification and are suitable for vegans and those with gluten sensitivities.
3. Variety of Programs: Toxin Rid offers detox programs ranging from one to ten days. This flexibility allows users to select a program that fits their level of toxin exposure and time available before their drug test.

Cons

Despite its benefits, Toxin Rid has some drawbacks:

1. Potential Side Effects: Some users have experienced side effects such as diarrhea, which can be uncomfortable and inconvenient.
2. High Cost: Toxin Rid is relatively expensive compared to other detox products. This higher price can be a barrier for those on a tight budget.
3. Mixed Customer Reviews: While many people have had positive results, there are mixed reviews. Heavy cannabis users, in particular, may find it challenging to achieve the desired results, and there have been reports of issues with refunds and the product not working as expected for some users.

In conclusion, Toxin Rid offers a natural and flexible detox solution with proven effectiveness for many users. However, its cost and potential side effects, along with varied customer experiences, are important factors to consider before choosing it for your detox needs.

Q&A Insights

If you’re worried about passing a drug test and considering Toxin Rid, here are some key answers to common questions:

1. Is Toxin Rid detectable in lab tests? No, Toxin Rid is generally undetectable by lab tests. The product works to cleanse toxins from your body naturally, so it doesn’t leave behind any traces that would be flagged by a lab. However, it’s still a good idea to avoid bringing the product to the testing lab to prevent any potential issues.

2. Can Toxin Rid help with alcohol or opiate drug tests? Yes, Toxin Rid can be effective for various types of drug tests, including those for alcohol and opiates. For alcohol, it’s best to abstain from drinking on the day of your test, as alcohol leaves the body quickly. For opiates, using Toxin Rid along with vitamin B and creatinine supplements on the test day can boost its effectiveness.

3. How long does Toxin Rid’s effect last? The effect of Toxin Rid typically lasts up to five hours. The duration can vary depending on the detox program you use and how frequently you’ve been exposed to toxins. For the best results, it’s important to follow the detox program closely and avoid reintroducing toxins into your system.

4. Are there quick detox options with Toxin Rid? Yes, Toxin Rid offers shorter detox programs, including a one-day option for those who need fast results. This can be useful if you’re facing an imminent drug test and need a rapid way to cleanse your system.

5. How does Toxin Rid compare to other detox methods? Toxin Rid stands out because it provides a natural approach to detoxification without relying on synthetic urine or harsh methods. It is easy to use and comes in a range of detox programs suited to different levels of toxin exposure, making it a versatile choice for many users.

In summary, Toxin Rid is designed to help you pass drug tests effectively, with options available for both quick and extended detox needs. By following the program guidelines and combining it with appropriate supplements, you can increase your chances of passing your drug test and keeping your job prospects intact.

COMPANY VIGOROUSLY DEFENDS ITS TUSSI-12^®D TABLETS AND TUSSI-12^®DS SUSPENSION

Somerset, NJ – November 22, 2004 – MedPointe Pharmaceuticals responded today to recent developments concerning its continued efforts to enforce its intellectual property rights covering its TUSSI-12^®D product line.

MedPointe’s TUSSI-12^®D brand products are covered by U.S. Patent No. 6,417,206 (“the ‘206 patent”). MedPointe has previously successfully enforced this patent against certain manufacturers to prevent infringement, obtaining consent orders and preliminary injunctions from the U.S. District Court for the District of New Jersey that prevent these parties from offering to sell or selling generic versions of MedPointe’s patented TUSSI- 12^®D products.

Although a panel of an appellate court on November 17, 2004 issued an opinion that the preliminary injunction against Hi-Tech Pharmacal Co., Inc., Amityville, NY, should be vacated, MedPointe believes that the preliminary injunction remains in full force and effect, unless and until the appellate court issues a mandate vacating it. Among other things, the preliminary injunction prevents Hi-Tech Pharmacal Co., Inc. from shipping, manufacturing, having manufactured, offering to sell, selling, or importing into the U.S. Tannate 12 D S, a generic version of MedPointe’s TUSSI-12^®DS brand suspension product.

On November 19, 2004, Hi-Tech Pharmacal Co., Inc. issued a press release stating that it “plans to begin shipments of its Tannate 12 D S cough and cold product in the near future” but that it “may still be subject to liability based on a claim of patent infringement for sales of Tannate 12 D S.” MedPointe believes that Hi-Tech Pharmacal Co., Inc. remains bound by the preliminary injunction and may not ship, manufacture, have manufactured, offer to sell, sell, or import into the U.S. Tannate 12 D S, unless and until the District Court, acting on a mandate by the appellate court, lifts that injunction.

MedPointe believes that the panel opinion of the appellate court is in error, and agrees with the Chief Judge of the appellate court, who dissented from the panel opinion. MedPointe intends to petition for a rehearing to overturn the opinion and prevent the issuance of any mandate vacating the injunction.

MedPointe notes that even if the preliminary injunction is lifted, the panel of the appellate court stated that its decision “in no way resolves the ultimate question of validity” of MedPointe’s ‘206 patent.

MEDPOINTE PHARMACEUTICALS
MedPointe Pharmaceuticals is a privately held, specialty pharmaceutical company located at 265 Davidson Avenue, Somerset, New Jersey, 08873-4120; 732-564-2200. MedPointe specializes in respiratory, allergy, central nervous system, cough-cold, and pediatric products. The company maintains a manufacturing facility in Decatur, Illinois. For more information on MedPointe, visit www.medpointepharma.com.

Somerset, NJ – November 10, 2004 – The Institute of Packaging Professionals (IoPP) has recognized MedPointe’s ASTELIN Ready-Spray^TM with an AmeriStar Award for excellence in consumer product package design in the pharmaceutical/drug category. Ronald Jaketic, Manager of Engineering Projects for MedPointe, accepted the award on behalf of MedPointe at the PACK EXPO International Show 2004 on November 9 in Chicago, Ill.

The award recognizes the innovative new package design for the company’s leading prescription intranasal antihistamine, ASTELIN (azelastine hydrochloride) Nasal Spray, 137 mcg. Introduced in April, the redesigned package offers a new 30 mL bottle featuring a convenient, preassembled spray pump unit and a patented, V-shaped bottom to maximize utilization.

“This new ASTELIN package was designed to provide consumers with a more user-friendly product,” said Paul Edick, President of MedPointe. “We are honored that the IoPP has acknowledged our efforts to enhance patient benefit and increase the product’s ease-of-use.”

The Institute of Packaging Professionals is the leading North American Individual membership organization serving professionals in the packaging community. Each year the organization recognizes industry leaders for innovative and pioneering packaging design at its PACK EXPO International Show.

ABOUT ASTELIN READY-SPRAY, 30 ML

ASTELIN is the fastest-growing antihistamine in new prescriptions since April 2004. ASTELIN Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis (in patients five years of age and older) and nonallergic vasomotor rhinitis (in patients 12 years of age and older). According to the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology, intranasal antihistamines such as ASTELIN are recommended as first-line treatment for allergic rhinitis. ASTELIN Nasal Spray is well tolerated and relieves a full range of rhinitis symptoms, including tough-to-treat nasal congestion. The most commonly reported adverse events in seasonal allergic rhinitis and nonallergic vasomotor rhinitis patients 12 years of age and older were bitter taste, headache, somnolence, and nasal burning. The adverse event profile in seasonal allergic rhinitis patients five to 11 years of age was similar to that in the adult population.

MEDPOINTE PHARMACEUTICALS
MedPointe Pharmaceuticals is a privately held, specialty pharmaceutical company located at 265 Davidson Avenue, Somerset, New Jersey, 08873-4120; 732-564-2200. MedPointe specializes in respiratory, allergy, central nervous system, cough-cold, and pediatric products. The company maintains a manufacturing facility in Decatur, Illinois. For more information on MedPointe, visit www.medpointepharma.com.

For additional information and/or full prescribing information on ASTELIN® (azelastine hydrochloride) Ready-Spray^TM, please call 1-800-598-4856 or visit ASTELIN’s new web site at www.astelin.com.

Total Wallace Rx Promotional Efforts to Exceed 300 Sales Representatives; Innovex to Provide Sales Force Recruitment and Training

Cranbury, NJ and Parsippany, NJ – January 14, 2002 – MedPointe Inc. and its Wallace Pharmaceuticals Division announced today that they have hired Innovex, a unit of Quintiles Transnational Corp. (NASDAQ: QTRN), to recruit and provide training support for approximately 120 new sales representatives and managers to accelerate sales of several key MedPointe prescription pharmaceutical products. The addition of these 120 individuals to the promotional effort behind MedPointe’s prescription pharmaceutical line will increase MedPointe’s total US promotional field force to approximately 300 persons.

The agreement between MedPointe and Innovex includes the selling effort behind one of MedPointe’s flagship brands, ASTELIN®, its unique nasal spray to treat allergic and non-allergic rhinitis. The Innovex sales managers and representatives will work closely with sales management at MedPointe’s Wallace Pharmaceuticals Division in their commercialization efforts. Under the agreement, Innovex will provide proactive recruiting services based on a wide range of proprietary recruiting resources and methods. Also, as part of this agreement, Innovex will provide consulting services to accelerate Wallace Pharmaceuticals’ sales training programs in order to place qualified sales representatives in the field as quickly as possible.

“This represents an important step forward in our plans to enhance the commercial impact of our portfolio, especially our major respiratory therapeutic, ASTELIN®,” said James S. Burns, MedPointe’s President and Chief Operating Officer. Gary Evans, Vice President-Field Sales, said, “Our product line responds well to direct promotion by our field sales force. The Innovex arrangement allows us to achieve national coverage quickly in order to better support our growing ASTELIN® and RYNA/TUSSI® products.”

Richard Johnson, M.D., Chief Executive Officer, Quintiles Commercialization North America, said: “Providing ‘in-house’ recruiting and training services to build new sales forces can sometimes impose delays on a customer company’s operations. At Innovex, we specialize in rapid deployment of new sales forces to help accelerate customers’ sales. Innovex’s leading capabilities in sales force recruiting puts us at the forefront of this $200 million-dollar industry.”

About MedPointe
MedPointe Inc. is a privately held company located at Half Acre Road, Cranbury, New Jersey, 08512; 609-655-6000. Its prescription pharmaceutical products division, Wallace Pharmaceuticals, specializes in respiratory, pediatric and central nervous system therapies and maintains manufacturing facilities in Cranbury, New Jersey and Decatur, Illinois. Wampole Laboratories, MedPointe’s diagnostics division, distributes a wide range of immunoassay-based diagnostic tests for use by hospitals, physicians and reference laboratories. For more information on MedPointe, Wallace Pharmaceuticals or Wampole Laboratories, visit www.medpointeinc.com.

About Innovex
Innovex, a unit of Quintiles, is the world’s leading commercial solutions provider and offers sales and marketing services designed to accelerate the success of pharmaceutical, biotech and medical device products. Since 1996, Innovex has created more than 94 contract sales forces in the United States, with more than 12,500 representatives who have launched more than 100 established products and 37 new products. For more information, visit www.innovex.com.

Quintiles Transnational Corp. is the world’s leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles Transnational is a member of the S&P; 500 and Fortune 1000. For more information visit the company’s Web site at www.quintiles.com.

Backed by Investment Firms Carlyle and Cypress, Pharmaceutical Executives Set to Build Specialty Healthcare Products Company

Short Hills, NJ – May 8, 2001 – MedPointe Capital Partners, backed by private equity firms The Carlyle Group and The Cypress Group, announced this morning that it has entered into a definitive agreement to purchase the healthcare business of Carter-Wallace, Inc. (NYSE:CAR) in a cash deal valued at approximately $408 million.

In a separate transaction, Carter-Wallace has agreed to sell the assets of its consumer products business for approximately $739 million to Armkel, a partnership of consumer goods company Church & Dwight and the private equity group Kelso & Company. Both transactions must be approved by Carter-Wallace shareholders and receive clearance from various regulatory agencies. CPI Development Corporation, a private holding company that controls approximately 83 percent of the voting power of Carter-Wallace, has entered into an agreement to vote in favor of the transactions, subject to certain limited exceptions. The transactions are expected to be completed in late summer 2001.

In the deal, MedPointe is acquiring Wallace Laboratories, Carter-Wallace’s pharmaceutical arm, and Wampole Laboratories, its diagnostics unit, as well as the rights to the Carter-Wallace name. MedPointe, Carlyle and Cypress, which will collectively invest approximately $275 million in the transaction, were advised in the transaction by Bear, Stearns & Co. Inc., Simpson Thacher & Bartlett and PricewaterhouseCoopers LLP. Bear, Stearns & Co. Inc. has also provided a commitment for up to $225 million of senior bank debt.

“Carter-Wallace is a healthcare products company with a long history and strong assets,” said Anthony H. Wild, Ph.D., MedPointe’s Chairman and CEO. “The job now is to capitalize on those assets through increased emphasis on sales and marketing, product development and licensing. We have a long road ahead of us, but we are confident that the Carter-Wallace healthcare business provides an excellent platform for growth.”

MedPointe’s executives – who have spent most of their careers in the healthcare products industry – will assume senior operating positions at the company once the deal closes. Dr. Wild, who will become Chairman and CEO of the new company, is the former President of the Global Pharmaceutical Sector of Warner-Lambert, where he had worldwide responsibility for the company’s pharmaceutical operations, including research and development. During Dr. Wild’s tenure, he managed sales growth from $2.1 billion to $10 billion, the formation of the Sankyo/Parke-Davis joint venture, the global partnership with Pfizer to market the cholesterol-lowering drug Lipitor®, and the acquisitions of Jouveinal, Agouron, Hickson and gene/Networks.

The other three MedPointe executives will serve as Executive Vice Presidents in the new company, responsible for operations, administration and finance. The senior executive team includes James S. Burns, former Group President at Becton Dickinson and Vice Chairman of HealthCare Ventures; John T.W. Hawkins, former head of the Global Healthcare Sector at executive search firm Russell Reynolds Associates; and Paul S. Herendeen, former Executive Vice President and CFO of Warner Chilcott, a specialty pharmaceutical company recently merged with Galen Holdings, an Irish specialty pharmaceutical company.

MedPointe (www.medpointecapital.com), which is currently headquartered in Short Hills, New Jersey, was founded last year with the intention of building a specialty healthcare products company. “The scale of the large pharmaceutical and diagnostics companies today means that a great deal of emphasis is placed on ‘blockbuster’ products,” explained Dr. Wild. “As a result, there are many excellent mid-level products that don’t receive the support they should. These products may not make strategic sense to a ‘big pharma’ company, but we see a lot of opportunity in them.” After the closing of the sale, MedPointe will be headquartered in the current Carter-Wallace facility in Cranbury, New Jersey.

Dr. Wild and the MedPointe team were attracted to Wallace and Wampole Laboratories because they have a solid foundation of products, including the allergy medicine Astelin®, the muscle relaxant Soma®, the Rynatan/Tussi® cough-cold line and a range of professional laboratory and physician office diagnostic tests. The MedPointe strategy following completion of the deal calls for increased investment in product sales, increased emphasis on new product formulation, and further product acquisitions to accelerate the company’s growth.

The Carlyle Group is a global diversified private equity firm that originates, structures, and acts as an equity investor in management buyouts, corporate partnerships, platform consolidations, private placements and growth investments. Carlyle currently manages approximately $12 billion of capital across twelve institutional funds, including a $3.9 billion domestic leveraged buyout fund. Carlyle has completed approximately 215 transactions, investing over $5.8 billion of equity and purchasing more than $16.4 billion of assets.

The Cypress Group is a private equity investment fund whose objective is to achieve long-term capital appreciation through growth-oriented, privately negotiated equity investments. The Cypress Group currently manages over $3.5 billion of equity capital on behalf of major pension funds, university endowments and other leading financial institutions. To date, The Cypress Group has invested over $1.5 billion in nine transactions. As principals, The Cypress Group has invested a total of approximately $2.3 billion in 21 businesses with an aggregate transaction value of approximately $13.5 billion.

Backed by Investment Firms Carlyle and Cypress, Pharmaceutical Executives Create MedPointe Inc. and Complete the Acquisition of Carter-Wallace and its Healthcare Business

Cranbury, NJ – October 1, 2001 – A group of healthcare executives, backed by two leading private equity firms, announced today that it has completed the $408-million acquisition of the Healthcare Business and corporate stock of Carter-Wallace, Inc. (formerly NYSE:CAR). Carter-Wallace, Inc. has changed its name to MedPointe Inc.

This acquisition was led by a syndicate of private equity firms headed by The Carlyle Group and The Cypress Group. The syndicate also included Frazier & Company and Ferrer Freeman Thompson & Co. Through this transaction, the investor group acquired Carter-Wallace, Inc. and its two principal Healthcare Businesses, Wallace Pharmaceuticals, a prescription pharmaceutical division, and Wampole Laboratories, its medical diagnostics division.

The acquisition was funded with more than $500 million in equity and debt commitments, including more than $280 million from the equity investors. Bear, Stearns & Co. Inc., which underwrote the initial debt financing commitment, acted as Lead Arranger and Lehman Brothers acted as Co-Arranger for the syndication of $225 million of Senior Secured Credit Facilities in connection with the acquisition. Bear, Stearns & Co. Inc. also advised the equity investors.

“The successful completion of this acquisition concludes nearly a year of hard work by our management team, our investors and our employees and marks the birth of a new company,” said Anthony H. Wild, Ph.D., MedPointe Inc.’s Chairman and CEO. “The healthcare businesses of Carter-Wallace have provided MedPointe with strong operating management, an excellent foundation of products and two highly skilled sales forces. Through this acquisition, we have a wonderful starting point towards fulfilling the promise of MedPointe’s core mission: ‘making medicine better.'” MedPointe plans to pursue a variety of business development initiatives including product acquisitions, line extensions, licensing, co-promotion arrangements and reformulations.

The Wallace Pharmaceuticals product line includes the allergy medicine Astelin®, the only prescription antihistamine approved by the FDA for both seasonal allergic rhinitis and non-allergic (vasomotor) rhinitis. The Wallace line also includes the Rynatan/Tussi® cough-cold line, the muscle relaxant Soma® and the anticonvulsant Felbatol®. The Wampole product line includes a range of professional laboratory and physician office diagnostic products. “We believe that specialty products – marketed and managed effectively – offer substantial opportunities that MedPointe can bring to fruition,” explained Dr. Wild. “Not every product needs to be a ‘blockbuster’ drug in order to be a successful part of the healthcare products market.”

On a pro forma basis, for the twelve months ended March 31, 2001, MedPointe Inc. had consolidated net sales of approximately $220 million. As of October 1, 2001, MedPointe Inc. has approximately 525 full-time employees, including 275 in field sales and sales management.

The management team roster of MedPointe Inc. is comprised of senior, seasoned healthcare executives:

• Dr. Anthony H. Wild, Chairman and CEO of the new company, is the former President of the Global Pharmaceutical Sector of Warner-Lambert, where he had worldwide responsibility for the company’s pharmaceutical operations, including research and development. During Dr. Wild’s tenure, he managed Warner-Lambert’s pharmaceutical sales growth from $2.1 billion to $10 billion. In addition, he was responsible for the formation of the Sankyo/Parke-Davis joint venture, the global partnership with Pfizer to market the cholesterol-lowering drug Lipitor® and the acquisitions of Jouveinal, Agouron, Hickson and gene/Networks. He is a Founding Partner and CEO of MedPointe Capital Partners, LLC, a private equity capital partnership whose goal was to create a leading company in the specialty pharmaceutical arena.
• James S. Burns will serve as President and Chief Operating Officer of MedPointe Inc. He was a former Group President at Becton Dickinson, a founding Vice Chairman of HealthCare Ventures and a Partner at Booz Allen & Hamilton. He is a Founding Partner and Managing Director of MedPointe Capital Partners, LLC.
• John T.W. Hawkins will serve as MedPointe Inc.’s Executive Vice President, Corporate Development and External Affairs. Mr. Hawkins was the former Head of the Global Healthcare Sector at executive search firm Russell Reynolds Associates, and previously, an investment banker at Alex. Brown & Sons. He is also a Founding Partner and Managing Director of MedPointe Capital Partners, LLC.
• Paul S. Herendeen, Executive Vice President and Chief Financial Officer, brings more than 20 years of experience in the financial services and healthcare industries, most recently as Executive Vice President and Board Member of Galen plc, a public U.K.-based pharmaceutical company.
• Bernardo L. Tafur will serve as MedPointe Inc.’s Executive Vice President, Human Resources and Administration. He was formerly the Senior Vice President, Human Resources of Pfizer Inc.’s Pharmaceuticals Group.
• Beth P. Hecht, Senior Vice President, General Counsel and Secretary, has more than 14 years of corporate legal experience, having worked as Vice President, General Counsel and Secretary for Warner Chilcott plc, Alpharma Inc. and ChiRex, Inc.
• Thomas G. Gerstmyer will continue as President of Wallace Pharmaceuticals, the flagship pharmaceutical division of MedPointe Inc.
• John Bridgen, Ph.D., will continue as President of Wampole Laboratories, MedPointe Inc.’s medical diagnostics division.
• Gerald L. Messerschmidt, M.D., FACP, will serve as MedPointe Inc.’s Senior Vice President, Medical and Scientific Affairs. Prior to joining MedPointe Inc., he held senior executive positions at C.R. Bard, Inc., DNX Corporation and Ciba-Geigy Corporation.
• Bruce C. Friedman will serve as Corporate Vice President, Supply Chain Management. He previously served as Carter-Wallace Inc.’s Vice President, Operations for the Manufacturing Division.
• Timothy G. Henner will serve as Vice President and Corporate Controller of MedPointe Inc. Previously, he served as Carter-Wallace, Inc.’s Vice President and Controller, Manufacturing and Quality Control.
• Michael A. Tropiano will serve as Vice President and Corporate Treasurer of MedPointe Inc. He served previously as Carter-Wallace, Inc.’s Assistant Treasurer.

MedPointe Inc. has gathered a group of distinguished senior executives to constitute its Board of Directors. Dr. Wild will serve as Chairman of the newly formed board. MedPointe Inc. Board Members will also include Richard U. DeSchutter, retired Chairman and CEO of GD Searle and former Chairman & CEO of DuPont Pharmaceuticals; Ernest J. Larini, former Executive Vice President and Chief Financial Officer of Warner-Lambert Company; W. Robert Dahl, a Managing Director and Head of Healthcare investing at The Carlyle Group; Kenneth S. Abramowitz, a Managing Director at The Carlyle Group and former healthcare analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries; and William L. Spiegel, a Managing Director at The Cypress Group who leads the firm’s efforts in the healthcare and financial services sectors. Later this month, it is anticipated that The Cypress Group will nominate another Director for appointment to the Board.

MedPointe Inc. is a privately held company located at Half Acre Road, Cranbury, New Jersey, 08512; 609-655-6000. MedPointe expects to relocate to new corporate offices in Bridgewater, New Jersey in the second quarter of 2002. Its prescription pharmaceutical products division, Wallace Pharmaceuticals, specializes in respiratory, pediatric and central nervous system therapies and maintains manufacturing facilities in Cranbury, New Jersey and Decatur, Illinois. Wampole Laboratories, MedPointe’s diagnostics division, distributes a wide range of immunoassay-based diagnostic tests for use by hospitals, physicians and reference laboratories. For more information on MedPointe, Wallace Pharmaceuticals or Wampole Laboratories, visit www.medpointeinc.com.

Clinical Data Published in Leading Medical Journal as Fall Allergy Season Begins

Somerset, NJ – August 16, 2004 – ASTELIN^® Nasal Spray provided effective symptom relief for patients with moderate-to-severe seasonal allergic rhinitis who had an unsatisfactory response to treatment with Allegra^® (fexofenadine hydrochloride), according to a clinical study published in the August issue of Annals of Allergy, Asthma & Immunology.

“Our findings show that ASTELIN is an effective treatment option for patients with seasonal allergic rhinitis who do not respond well to fexofenadine,” reported Craig LaForce, MD, study investigator and Medical Director, North Carolina Clinical Research. “In fact, ASTELIN is an excellent alternative for patients who find themselves using multiple oral antihistamines or frequently switching antihistamines to find satisfactory relief.”

A similar study, published in the August 2003 issue of Annals of Allergy, Asthma & Immunology, showed ASTELIN to be an effective option for patients who had experienced unsatisfactory relief of moderate-to-severe allergic rhinitis symptoms with Claritin^® (loratadine).

“Given the growing body of clinical data that reinforces the efficacy of azelastine nasal spray in treating allergic rhinitis, ASTELIN should be considered an excellent option for first-line treatment,” commented Dr. LaForce.

Mid-August marks the beginning of the ragweed (fall allergy) season in much of the United States, according to the American Academy of Allergy, Asthma and Immunology.

THE STUDY
This was a multicenter, placebo-controlled, double-blind trial of 335 patients who had experienced unsatisfactory results with a seven-day course of fexofenadine monotherapy. Patients who had an inadequate response to fexofenadine were divided into three treatment groups: 1) ASTELIN Nasal spray and oral placebo; 2) ASTELIN Nasal Spray and fexofenadine; or 3) placebo nasal spray and oral placebo for a two-week treatment period. The TNSS – defined as the sum of individual symptom severity scores for runny nose, sneezing, itchy nose, and nasal congestion – determined drug efficacy.

After two weeks of treatment, the mean improvement from baseline in TNSS with ASTELIN Nasal Spray was significantly greater than with placebo. Further, the combination of ASTELIN and fexofenadine showed no additional clinical benefit compared to ASTELIN monotherapy.

ALLERGIC RHINITIS
Allergic rhinitis is the fifth most prevalent chronic disease in the United States, affecting up to 40 million adults and children each year. Allergic rhinitis costs the nation approximately $5.3 billion in direct and indirect costs (including time lost from work and school) and accounts for about 10,000 absences on a typical school day. It also can lead to complications, including sinusitis, Eustachian-tube dysfunction, ear infections, asthma, and sleep disturbances.

Current prescription and over-the-counter treatments include oral and intranasal antihistamines, oral and intranasal decongestants, intranasal corticosteroids, mast-cell stabilizers, and leukotriene- receptor antagonists. If the physician determines that allergen avoidance and pharmacotherapy do not provide sufficient relief, and if symptoms are sufficiently severe, he/she may suggest desensitization (immunotherapy).

ASTELIN® (AZELASTINE HYDROCHLORIDE) NASAL SPRAY, 137 MCG
ASTELIN Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis (patients five years of age and older) and nonallergic vasomotor rhinitis (patients 12 years of age and older). According to the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology, an intranasal antihistamine, such as ASTELIN, is recommended as first-line treatment for allergic rhinitis. ASTELIN is the only antihistamine approved for rhinitis patients with nasal congestion.

The most commonly reported adverse events in seasonal allergic rhinitis and nonallergic vasomotor rhinitis patients 12 years of age and older were bitter taste, headache, somnolence, and nasal burning. The adverse event profile in seasonal allergic rhinitis patients five to 11 years of age was similar to that in the adult population. Discontinuation rates due to adverse events in patients taking ASTELIN in the seasonal allergic rhinitis and nonallergic vasomotor rhinitis clinical trials were no different than those for placebo.

Please see full Prescribing Information, available at www.astelin.com.

MEDPOINTE PHARMACEUTICALS
MedPointe Pharmaceuticals is a privately held, specialty pharmaceutical company with headquarters at 265 Davidson Avenue, Somerset, New Jersey, 08873-4120; 732-564-2200. MedPointe, which specializes in allergy, respiratory, central nervous system, cough-cold, and pediatric products, has a manufacturing facility in Decatur, Illinois. For more information about the company, please visit www.medpointepharma.com.

For additional information and/or full Prescribing Information on ASTELIN Nasal Spray, please call 1-800-598-4856 or visit www.astelin.com.

Somerset, NJ and Rochester, NY – December 7, 2004 – MedPointe Pharmaceuticals announced today that its expanded sales force will now have sole responsibility for promoting MedPointe’s OPTIVAR^® (azelastine hydrochloride ophthalmic solution 0.05%) to the ophthalmic/eye-care community starting January 1, 2005. Bausch & Lomb, a global leader in eye health, had provided sales support for OPTIVAR after MedPointe acquired the medication in the second quarter of 2003. Since then, MedPointe has doubled its overall sales force in Primary Care and, most recently, expanded its Allergy Specialty sales force by 33 percent.

OPTIVAR is a sterile ophthalmic solution indicated for the treatment of itching of the eye associated with allergic conjunctivitis.

“While Bausch & Lomb has provided MedPointe with support in promoting OPTIVAR to eye-care specialists, we now have the resources and the capability to cover this important physician segment with the recent expansions of our Specialty Allergy and Primary Care field forces,” said Paul Edick, president of MedPointe. “We are committed to calling on selected ophthalmologists who treat allergic conjunctivitis patients, as well as the allergy, primary care, and ear, nose and throat specialists whom we normally see. The expansion of our allergy sales force to cover more eye-care physicians reaffirms our belief that OPTIVAR has great market potential, given its ability to target both the early- and late-phase allergic response in the eye.”

Paul G. Howes, Bausch & Lomb senior vice president and president of the Americas Region, said, “With the anticipated approval of new products in our own portfolio and a strategic review of our marketing priorities, Bausch & Lomb will focus on our own products. We wish MedPointe continued success with OPTIVAR.”

ABOUT OPTIVAR
OPTIVAR (azelastine hydrochloride ophthalmic solution, 0.05%) is a sterile ophthalmic solution indicated for the treatment of itching of the eye associated with allergic conjunctivitis in patients as young as 3 years of age. In controlled, multidose studies, the most frequently reported adverse events were transient eye burning/stinging, headache, and bitter taste. Discontinuation due to these adverse events was less than 1 percent. OPTIVAR is contraindicated in persons with known hypersensitivity to any of its components.

MEDPOINTE PHARMACEUTICALS
MedPointe Pharmaceuticals is a privately held, specialty pharmaceutical company located at 265 Davidson Avenue, Somerset, New Jersey, 08873-4120; 732-564-2200. MedPointe specializes in respiratory, allergy, central nervous system, cough-cold, and pediatric products. The company maintains a manufacturing facility in Decatur, Illinois. For more information on MedPointe, visit www.medpointepharma.com

For additional information and/or full Prescribing Information for OPTIVAR^®, please call 1-800-598-4856.

BAUSCH & LOMB
Bausch & Lomb is the eye health company, dedicated to perfecting vision and enhancing life for consumers around the world. Its core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical, and pharmaceutical products. The Bausch & Lomb name is one of the best known and most respected healthcare brands in the world. Celebrating its 150th anniversary, the Company is headquartered in Rochester, New York. Bausch & Lomb’s 2003 revenues were $2 billion; it employs approximately 11,500 people worldwide and its products are available in more than 100 countries. More information about the Company can be found on the Bausch & Lomb Web site at www.bausch.com. Copyright Bausch & Lomb.